Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist). It has been approved as a second line treatment option for better glycaemic control in type 2 diabetes and curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahapatra, Manoj Kumar, Karuppasamy, Muthukumar, Sahoo, Biswa Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8736331/
https://www.ncbi.nlm.nih.gov/pubmed/34993760
http://dx.doi.org/10.1007/s11154-021-09699-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8736331/
https://www.ncbi.nlm.nih.gov/pubmed/34993760
http://dx.doi.org/10.1007/s11154-021-09699-1

Ejemplares similares